In vitro and in vivo efficacy of a novel fluoro-ketolide HMR 3562 against enterococci

The in vitro activity of HMR 3562, a new 2-fluoro-ketolide drug, was invest igated against 95 enterococci, including 36 vancomycin-resistant strains. H MR 3562 inhibited 90% of enterococci susceptible or resistant to erythromyc in A at 0.005 and 0.6 mg/L, respectively. HMR 3562 was highly active in mur ine peritonitis induced by five enterococci, irrespective of resistance phe notype, displaying effective doses in the range 3.4-21.8 mg/kg. The results demonstrate the potential of HMR 3562 in the treatment of infections cause d by multiresistant enterococci.